Providers/Grant Support
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Credits Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
- Nurses — 1.0 Nursing Contact Hour
- PAs — maximum of 1.0 AAPA Category 1 CME credit
All other health care professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is intended for oncology clinicians (MD/DOs, NP/PAs, and nurses), with a secondary target audience that includes pathology and pulmonary clinicians (MD/DOs, NP/PAs, and nurses).
Program Overview
HER2 mutations in metastatic NSCLC may be uncommon, but missing them can mean missing a critical treatment opportunity. In this activity, you’ll uncover how HER2 (ERBB2) alterations drive tumor growth and why they’re linked to poorer outcomes and brain metastases. Learn how to apply next-generation sequencing (NGS) to identify eligible patients and interpret results that guide targeted therapy decisions. Explore emerging treatments, including HER2-directed agents, and how they reshape care for this subset of patients. Real-world insights will help you bridge the gap between testing and treatment. If you’re treating lung cancer, this is one biomarker you can’t afford to overlook.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Describe the epidemiology, molecular features, and clinical relevance of HER2 (ERBB2) mutations in mNSCLC, and differentiate them from other common oncogenic drivers
- Apply evidence-based guidelines for molecular testing in mNSCLC and interpret HER2 (ERBB2) mutation results from NGS reports using best practices
- Evaluate current and emerging therapies for HER2 (ERBB2)-mutant mNSCLC, with emphasis on agents targeting tyrosine kinase domain activating mutations
Faculty
Jessica Bauman, MD
Chief, Division of Head and Neck Medical Oncology
Fox Chase Cancer Center
Philadelphia, PA
Oleg Gligich, MD
Head of Thoracic Oncology
Mount Sinai Medical Center
Miami Beach, FL
Rohit Kumar, MD
Interim Chair, Department of Medicine
Professor of Pulmonary, Interventional, and Critical Care Medicine
Fox Chase Cancer Center
Philadelphia, PA
Eric Vail, MD
Director, Molecular Pathology Laboratories
Associate Professor, Pathology and Laboratory Medicine
Cedars‑Sinai Medical Center
Los Angeles, CA
Brittany Steinfeld, PA
Medical Oncology
Mount Sinai Medical Center
Miami Beach, FL
Kimberly Martins, AGACNP-BC
Medical Oncology
Mount Sinai Medical Center
Miami Beach, FL
Margaret Das, PhD
Medical Writer
The France Foundation
Old Lyme, CT
Accreditation Statement
In support of improving patient care, The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Credit Designation
Physician Credit Designation
The France Foundation designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
The France Foundation designates this activity for 1.0 contact hour.
Physician Associates
The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until April 29, 2027. PAs should only claim credit commensurate with the extent of their participation.
All other health care professionals completing this course will be issued a statement of participation.
Disclosures of Conflicts of Interest
Jessica Bauman, MD
Faculty
No relevant financial disclosures
Oleg Gligich, MD
Faculty
No relevant financial disclosures
Rohit Kumar, MD
Faculty
No relevant financial disclosures
Eric Vail, MD
Faculty
Consultant for AbbVie, Amgen, AstraZeneca, Bayer, BMS, Eli Lilly, Illumina, Pfizer, Sanofi, and Thermo Fisher
Brittany Steinfeld, PA
Planning Committee Member
No relevant financial disclosures
Kimberly Martins, AGACNP-BC
Planning Committee Member
No relevant financial disclosures
Margaret Das, PhD
Planning Committee Member, TFF Content Reviewer
No relevant financial disclosures
Miriam Giles
TFF Activity Staff
No relevant financial disclosures
Amanda Noe
TFF Activity Staff
No relevant financial disclosures
Instructions for Participation and Credit
There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the activity, and completing the posttest and evaluation form. A score of at least 67% on the posttest is required to successfully complete this activity. The participant may take the test until successfully passed.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones and Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
The France Foundation requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: The France Foundation at 860-434-1650 or [email protected]